Basic Considerations for the Use of Monoclonal Antibodies in Migraine
ConclusionsThe CGRP mAbs are an innovative new therapy for migraine and address the need for effective and tolerable preventive options. MAbs, including those that target CGRP or its receptor, bind to a target with high specificity and affinity and lead to few off ‐target adverse effects, although mechanism‐based adverse reactions may occur. Unlike other therapeutic antibodies used to treat neurologic disease, CGRP mAbs do not have a target within the immune system and have been designed to avoid altering the immune system. The safety and efficacy of mAbs against CGRP or its receptors are being investigated in clinical development programs, and the first of these therapies has received regulatory approval in the United States.
Source: Headache: The Journal of Head and Face Pain - Category: Neurology Authors: Morris Levin,
Stephen D. Silberstein,
Robert Gilbert,
Sylvia Lucas,
Leanne Munsie,
Alyssa Garrelts,
Kate Kennedy,
Nicole Everman,
Eric Pearlman Tags: Headache Currents Source Type: research
More News: Brain | Child Development | Children | Genetics | Headache | Migraine | Neurology | Pain | Study | USA Health